Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044617 | 0.85 | MAOB (0.35) | MAOBMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL4041245 | 0.75 | MEN1 (0.39) | MAOBMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL4045158 | 0.73 | MEN1 (0.37) | MAOBMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL6015158 | 0.72 | MEN1 (0.52) | MAOBMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL10382659 | 0.70 | MAOB (0.64) | MAOBMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL4042219 | 0.66 | UGCG (0.46) | MEN1KMT2AATM | |
| SCHEMBL4044374 | 0.65 | CA12 (0.42) | MEN1KMT2AHSP90AA1CA2 | |
| SCHEMBL4039759 | 0.64 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL9536771 | 0.63 | MAOB (0.61) | MAOBMEN1KMT2APRKCZ | |
| SCHEMBL9536658 | 0.62 | MAOB (0.64) | MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225081-A1 | Pyridazinones and triazinones and medicinal use thereof | GRIK1, GRIK3, GRIK2 | MAOB 1856/4885MEN1 3727/4885KMT2A 721/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | MAOB 1378/4885MEN1 2326/4885KMT2A 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.